Fibrolamellar hepatocellular carcinoma

WikiDoc Resources for Fibrolamellar hepatocellular carcinoma
Articles
Most recent articles on Fibrolamellar hepatocellular carcinoma Most cited articles on Fibrolamellar hepatocellular carcinoma Review articles on Fibrolamellar hepatocellular carcinoma Articles on Fibrolamellar hepatocellular carcinoma in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Fibrolamellar hepatocellular carcinoma Images of Fibrolamellar hepatocellular carcinoma Photos of Fibrolamellar hepatocellular carcinoma Podcasts & MP3s on Fibrolamellar hepatocellular carcinoma Videos on Fibrolamellar hepatocellular carcinoma
Evidence Based Medicine
Cochrane Collaboration on Fibrolamellar hepatocellular carcinoma Bandolier on Fibrolamellar hepatocellular carcinoma TRIP on Fibrolamellar hepatocellular carcinoma
Clinical Trials
Ongoing Trials on Fibrolamellar hepatocellular carcinoma at Clinical Trials.gov Trial results on Fibrolamellar hepatocellular carcinoma Clinical Trials on Fibrolamellar hepatocellular carcinoma at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Fibrolamellar hepatocellular carcinoma NICE Guidance on Fibrolamellar hepatocellular carcinoma NHS PRODIGY Guidance FDA on Fibrolamellar hepatocellular carcinoma CDC on Fibrolamellar hepatocellular carcinoma
Books
Books on Fibrolamellar hepatocellular carcinoma
News
Fibrolamellar hepatocellular carcinoma in the news Be alerted to news on Fibrolamellar hepatocellular carcinoma News trends on Fibrolamellar hepatocellular carcinoma
Commentary
Blogs on Fibrolamellar hepatocellular carcinoma
Definitions
Definitions of Fibrolamellar hepatocellular carcinoma
Patient Resources / Community
Patient resources on Fibrolamellar hepatocellular carcinoma Discussion groups on Fibrolamellar hepatocellular carcinoma Patient Handouts on Fibrolamellar hepatocellular carcinoma Directions to Hospitals Treating Fibrolamellar hepatocellular carcinoma Risk calculators and risk factors for Fibrolamellar hepatocellular carcinoma
Healthcare Provider Resources
Symptoms of Fibrolamellar hepatocellular carcinoma Causes & Risk Factors for Fibrolamellar hepatocellular carcinoma Diagnostic studies for Fibrolamellar hepatocellular carcinoma Treatment of Fibrolamellar hepatocellular carcinoma
Continuing Medical Education (CME)
CME Programs on Fibrolamellar hepatocellular carcinoma
International
Fibrolamellar hepatocellular carcinoma en Espanol Fibrolamellar hepatocellular carcinoma en Francais
Business
Fibrolamellar hepatocellular carcinoma in the Marketplace Patents on Fibrolamellar hepatocellular carcinoma
Experimental / Informatics
List of terms related to Fibrolamellar hepatocellular carcinoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: Fibrolamellar carcinoma; FLC

Overview

Fibrolamellar hepatocellular carcinoma (FLC) is a rare subtype of primary liver cancer. Fibrolamellar hepatocellular carcinoma was first described Edmondson in 1956. Fibrolamellar hepatocellular carcinoma most commonly in children and young adults.

Historical Perspective

• Fibrolamellar hepatocellular carcinoma was first described Edmondson in 1956.

Classification

• There is no classification for fibrolamellar hepatocellular carcinoma.

Pathophysiology

• The pathogenesis of fibrolamellar hepatocellular carcinoma is characterized by:

• Lack of cirrhosis

• The overexpression of DNAJB1-PRKACA gene has been associated with the development of fibrolamellar hepatocellular carcinoma.
• On gross pathology characteristic findings of fibrolamellar hepatocellular carcinoma, include:

• Hard, scirrhous, and well-circumscribed
• Tumor bulging
• white-brown tumor with fibrous bands throughout and central stellate scar

• On microscopic histopathological analysis, characteristic findings of fibrolamellar hepatocellular carcinoma, include:

• Tumor cells grow in sheets
• Trabeculae that are separated by collagen bundles (lamellar pattern)
• Large cells that contain abundant mitochondria
• Coarsely granular cytoplasm

Causes

• Common causes of fibrolamellar hepatocellular carcinoma, include:

• Active hepatic inflammation
• Hepatitis B or C viral infection
• Alcohol-related liver disease
• Nonalcoholic fatty liver disease
• Dietary aflatoxin B1

Differentiating Fibrolamellar Hepatocellular Carcinoma from Other Diseases

• Fibrolamellar hepatocellular carcinoma must be differentiated from other diseases that cause abdominal pain, weight loss, and malaise such as:

• Hepatocellular carcinoma
• Focal nodular hyperplasia
• Hepatic adenoma
• Hepatic metastasis

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In 2012, the incidence of fibrolamellar hepatocellular carcinoma was estimated to be 0.02 cases per 100,000 individuals in United States.

Age

• Fibrolamellar hepatocellular carcinoma is more commonly observed among patients aged 15 to 30 years old.
• Fibrolamellar hepatocellular carcinoma is more commonly observed among young patients.

Gender

• Fibrolamellar hepatocellular carcinoma affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

Risk Factors

• There are no risk factors for the development of fibrolamellar hepatocellular carcinoma.

Natural History, Complications and Prognosis

• The majority of patients with fibrolamellar hepatocellular carcinoma remain asymptomatic for years.
• Early clinical features include abdominal pain, weight loss, and malaise.
• If left untreated, the majority of patients with fibrolamellar hepatocellular carcinoma may progress to develop metastasis to abdominal lymph nodes, peritoneum, and lung.
• Common complications of fibrolamellar hepatocellular carcinoma, include:

• Hepatic failure
• Gynecomastia

• Prognosis will depend on stage at diagnosis. The average survival of patients with fibrolamellar carcinoma in the United States is 73% at 1 year and 32% at 5 years.

Diagnosis

Diagnostic Criteria

• The diagnosis of fibrolamellar hepatocellular carcinoma is made with the following diagnostic criteria:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• Fibrolamellar hepatocellular carcinoma is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• Fibrolamellar hepatocellular carcinoma may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].